RxDoctor Payments Data

Hadeel Kado, MD

Family Medicine · Troy, MINPI 1326010760

Payments from drug & device makers

$2,765in general payments, 2019–2025

Across 162 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$691
  • Pfizer$476
  • Amgen$313
  • Lilly USA, LLC$265
  • GSK$228
  • Shield Therapeutics Inc$152
  • plus $639 from 13 others

What the payments were for

  • Food & beverage$2,765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,765 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$61,921
Medicare patients
142
Services billed
993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$75,951
JardianceEmpagliflozin36$54,696
FarxigaDapagliflozin Propanediol35$41,152
RybelsusSemaglutide20$37,359
MounjaroTirzepatide31$33,685
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$27,286
EliquisApixaban14$24,680
XareltoRivaroxaban22$18,358
JanuviaSitagliptin Phosphate17$14,899
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,837
Janumet XrSitagliptin Phos/Metformin Hcl13$8,448
Atorvastatin Calcium444$5,008
SynthroidLevothyroxine Sodium29$3,549
Rosuvastatin Calcium134$1,885
Losartan Potassium162$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$691$113,31075 claims
GSKTrelegy Ellipta, Anoro Ellipta$228$38,12251 claims
Lilly USA, LLCMounjaro$265$33,68531 claims
PfizerEliquis$476$24,68014 claims
Johnson & JohnsonXarelto$34$18,35822 claims
AbbVieSynthroid$94$3,54929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →